Is Compounded Semaglutide Still Legal in 2026?

For a couple of years, "compounded semaglutide" was everywhere — cheap GLP-1 weight-loss programs from telehealth sites and med-spas, often a fraction of the price of brand-name Wegovy or Ozempic. That whole market existed because of a drug shortage. In 2025 the shortage officially ended, and the legal ground under mass-compounded semaglutide largely went with it. Here is what changed, what is still allowed, and why the cheap-version era is mostly over.

Why compounded semaglutide was legal in the first place

US law lets compounding pharmacies make a version of an FDA-approved drug under specific circumstances — and one of the biggest is a drug shortage. When the FDA lists a drug as in shortage, both state-licensed 503A pharmacies and larger 503B outsourcing facilities can compound copies to fill the gap, even though those copies are not themselves FDA-approved. Semaglutide spent a long stretch on that shortage list, which is exactly why a sprawling compounded market sprang up around it. The key thing to understand: that legality was always tied to the shortage, not to compounded semaglutide being approved on its own merits.

What changed in 2025

The pivot point was February 21, 2025, when the FDA declared the semaglutide shortage resolved for all dose presentations¹. Once a drug comes off the shortage list, the legal basis for compounding copies of it largely disappears. The FDA gave compounders a short wind-down rather than an overnight cutoff: it said it would not act against 503A pharmacies until April 22, 2025, and against 503B outsourcing facilities until May 22, 2025¹. After those dates, routinely compounding "essentially a copy" of FDA-approved semaglutide is no longer covered by the shortage exception.

An industry group sued to challenge the shortage determination, but in April 2025 a federal court declined to block the FDA, leaving the wind-down in place¹. So as a practical matter, the large-scale, mass-marketed compounded-semaglutide programs lost their legal footing across spring 2025.

What's still allowed in 2026 — and what isn't

This is where the honest nuance lives, because "compounded semaglutide is illegal now" is too blunt.

Traditional, patient-specific 503A compounding still exists. A licensed pharmacy can still compound a medication for an individual patient when there is a genuine clinical reason a commercially available product won't work — for example, a documented allergy to an inactive ingredient, or a needed change in form or strength that the approved product can't provide. What is not allowed is using "compounding" as a cover for cheaply mass-producing copies of an available, approved drug. The line is the difference between a tailored clinical need and a price play.

Salt forms were never the workaround they were sold as. Many cheap products used semaglutide sodium or acetate — salt forms — which the FDA has flagged as not the same active ingredient as the approved semaglutide base, and not appropriate for this kind of compounding. A product marketed as "research" semaglutide or a "semaglutide salt" is not a legitimate version of the drug.

The endgame is heading toward a permanent door-close. In April 2026, the FDA proposed to exclude semaglutide (along with tirzepatide and liraglutide) from the 503B "bulk drug substances" list, concluding there is no clinical need for outsourcing facilities to compound it from bulk powder now that the shortage is over². The proposal opened a public comment period running to June 29, 2026². If finalized, it would cement the exclusion rather than leave any ambiguity — making clear the shortage-era market is not coming back.

The safety reason this matters

The legal change is not just bureaucratic — it tracks a real safety story. Compounded semaglutide is not FDA-evaluated for safety, effectiveness, or quality, and the way it was sold created specific hazards. A poison-center case series documented patients self-administering 10-fold overdoses of compounded semaglutide drawn from multi-dose vials — because the vials lacked the safety features of a manufactured pen, the syringes weren't designed for the drug, and the dosing units (milligrams vs units vs milliliters) confused people³. A broader pharmacovigilance analysis of adverse-event reports for compounded GLP-1 products echoed the concern, finding a notable burden of medication errors and adverse events tied to these unstandardized products⁴. The FDA has cited hundreds of adverse-event reports linked to compounded semaglutide as part of its rationale². None of this means every compounded dose is dangerous — but it does mean the cheap version traded away the dose-accuracy and quality controls that come standard with the approved product.

What this means if you're shopping for semaglutide

Practically, in 2026, if you are offered "compounded semaglutide" at a too-good-to-be-true price, treat it skeptically: the broad legal basis for that product ended in 2025, and what remains legitimate is narrow, patient-specific compounding for a real clinical reason — not bulk weight-loss programs. The mainstream, fully legal options are the FDA-approved products: injectable Wegovy and Ozempic, the diabetes pill Rybelsus, and now the oral Wegovy 25 mg pill approved for weight management. They cost more, but they are standardized and overseen. If cost is the issue — which it usually is — the better path is working the legitimate levers: manufacturer savings programs and coverage. We break those down in Wegovy cost & savings and does insurance cover Wegovy and Ozempic?. For how the brand-name options compare, see Ozempic vs Wegovy, our pillar Semaglutide: how it works, results & side effects, and our best semaglutide guide.